Active, not recruiting
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (VOYAGER)
Real-World, Long-Term Data Collection to Gain Clinical Insights Into Roche Ophthalmology Products (VOYAGER STUDY)
- Sponsor
- Hoffmann-La Roche (Industry)
- Enrolment
- 6,000 planned
- Conditions
- Neovascular Age-related Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion; Branch Retinal Vein Occlusion; Central Retinal Vein Occlusion; Hemi-retinal Vein Occlusion
- Interventions
- Faricimab; Port Delivery System with Ranibizumab
- Ages
- adults, older adults
- Registry
- NCT05476926
From the registry
The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products in approved retinal indications (Faricimab for neovascular age-related macular degeneration \[nAMD\], diabetic macular edema \[DME\], and retinal vein occlusion; Port Delivery System with Ranibizumab for nAMD) in routine clinical practice. This study will not provide or make recommendations on use of any products including Roche products; treatment decisions will be determined by the treating physician and must be made independently to the decision to participate in this study. Participation in this study will not change or influence a patient's standard of care in any way.
Primary outcomes
- Change in Visual Acuity from Baseline at 1 Year, per Approved Retinal Indication and Product